Hypersensitivity reactions to ophthalmic products

Current Pharmaceutical Design

Volumn 12, Issue 26, 2006, Pages 3401-3410

  Ventura, Maria Teresa ^a   Viola, M ^b   Gaeta, F ^b   Di Leo, E ^a   Buquicchio, R ^a   Romano, A ^b,c  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Eye drops; Hypersensitivity reactions; Ophthalmic products; Patch tests; Preservatives

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS ACTING ON THE EYE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANESTHETIC AGENT; ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; APRACLONIDINE; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOPENTOLATE; DIPIVEFRINE; DORZOLAMIDE; HOMATROPINE; IMMUNOGLOBULIN E; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLEPHRINE; POLYPEPTIDE ANTIBIOTIC AGENT; PROSTAGLANDIN DERIVATIVE; RIFAMYCIN; SULFONAMIDE; TIMOLOL; UNINDEXED DRUG;

ANAPHYLAXIS; ASTHMA; BASOPHIL; BLEPHARITIS; BLURRED VISION; BRONCHOSPASM; CATARACT; CONGESTIVE HEART FAILURE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTACT DERMATITIS; DELAYED HYPERSENSITIVITY; DIAGNOSTIC TEST; DISEASE EXACERBATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; ECZEMA; ERYTHEMA; ERYTHRODERMA; EYELID DISEASE; EYELID EDEMA; FATIGUE; GLAUCOMA; HEADACHE; HEART BLOCK; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOASSAY; INTRACUTANEOUS TEST; INTRAOCULAR HYPERTENSION; LYMPHOCYTE TRANSFORMATION TEST; MAST CELL; NAUSEA; PATCH TEST; PATHOGENESIS; PRICK TEST; PRIORITY JOURNAL; PRURITUS; RETINA DETACHMENT; REVIEW; SEDATION; SIDE EFFECT; SWEATING; TACHYCARDIA; URTICARIA; VOMITING;

ADMINISTRATION, TOPICAL; ANTI-ALLERGIC AGENTS; DRUG HYPERSENSITIVITY; EYE; HUMANS; OPHTHALMIC SOLUTIONS; SYMPATHOMIMETICS;

EID: 33748544597     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778194024     Document Type: Review

References (104)

1. Herbst RA, Maibach HI. Contact dermatitis caused by allergy to ophthalmics: an update. Contact Dermatitis 1992; 27: 335-6.
2. Guin JD. Eyelid dermatitis: experience in 203 cases. J Am Acad Dermatol 2002; 47: 755-65.
3. Guin JD. Eyelid dermatitis: a report of 215 patients. Contact Dermatitis 2004; 50: 87-90.
4. Ventura MT, Di Corato R, Di Leo E, Foti C, Buquicchio R, Sborgia C, et al. Eyedrop-induced allergy: clinical evaluation and diagnostic protocol. Immunopharmacol Immunotoxicol 2003; 25: 529-38.
5. Manni G, Centofanti M, Sacchetti M, Oddone F, Bonini S, Parravano M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004; 13: 163-7.
6. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, el al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
7. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93.
8. Herbst RA, Uter W, Pirker C, Geier J, Frosch PJ. Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period. Contact Dermatitis 2004; 51: 13-9.
9. Aquilera L, Martinez-Bourio R, Cid C, Arino JJ, Saez de Equilaz JL, Arizaga A. Anaphylactic reaction after atropine. Anaesthesia 1988; 43: 955-7.
10. de Misa RF, Suarez J, Feliciano L, Lopez B. Allergic periocular contact dermatitis due to atropine. Clin Exp Dermatol 2003; 28: 97-8.
11. Decraene T, Goossens A. Contact allergy to atropine and other mydriatic agents in eye drops. Contact Dermatitis 2001; 45: 309-10.
12. Muñoz-Bellido FJ, Beltran A, Bellido J. Contact urticaria due to cyclopentolate hydrochloride. Allergy 2000; 55: 198-9.
13. Helton J, Storrs FJ. Pilocarpine allergic contact and photocontact dermatitis. Contact Dermatitis 1991; 25: 133-4.
14. Ortiz FJ, Postigo C, Ivars J, Ortiz PL, Merino V. Allergic contact dermatitis from pilocarpine and thimerosal. Contact Dermatitis 1991; 25: 203-4.
15. Cusano F, Luciano S, Capozzi M, Verrilli DA. Contact dermatitis from pilocarpine. Contact Dermatitis 1993; 29: 99.
16. Villareal O. Reliability of diagnostics tests for contact allergy to mydriatic eyedrops. Contact Dermatitis 1998; 38: 150-4.
17. Thomas P, Rueff F, Przybilla B. Severe allergic contact blepharo-conjunctivitis from phenylephrine in eyedrops, with corresponding T-cell hyper-responsiveness in vitro. Contact Dermatitis 1998; 38: 41-3.
18. Gonzalo-Garijo MA, Perez-Calderon R, de Argila D, Rodriguez-Nevado I. Erythrodermia to pseudoephedrine in a patient with contact allergy to phenylephrine. Allergol Immunopathol (Madr) 2002; 30: 239-42.
19. Erdmann SM, Sachs B, Merk HF. Allergic contact dermatitis from phenylephrine in eyedrops. Am J Contact Dermat 2002; 13: 37-8.
20. Parra A, Casas L, Tombo MJ, Yañez M, Vila L. Contact dermatitis from dipivefrine with possible cross-reaction to epinephrine. Contact Dermatitis 1998; 39: 325-6.
21. Vilaplana J, Zaballos P, Romaguera C. Contact dermatitis by dipivefrine. Contact Dermatitis 2005; 52: 169-70.
22. Akita H, Akamatsu H, Matsunaga K. Allergic contact dermatitis due to phenylephrine hydrochloride, with an unusual patch test reaction. Contact Dermatitis 2003, 49: 232-5.
23. Armisen M, Vidal C, Quintans R, Suarez A, Castroviejo M. Allergic contact dermatitis from apraclonidine. Contact Dermatitis 1998; 39: 193.
24. Silvestre JF, Camero L, Ramon R, Albares MP, Botella R. Allergic contact dermatitis from apraclonidine in eyedrops. Contact Dermatitis 2001; 45: 251.
25. Shin DH, Glover BK, Cha SC, Kim YY, Kim C, Nguyen KD. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am J Ophthalmol 1999; 127: 511-5.
26. Geyer O, Schmidt KG, Pianka P, Neudorfer M, Lazar M. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.Graefes Arch Clin Exp Ophthalmol 2000; 238: 149-52.
27. Diggory P, Cassels-Brown A, Vail A, Abbey LM, Hillman JS. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345: 1604-6.
28. Girardin P, Derancourt C, Laurent R. A new cutaneous side-effect of ocular beta-blockers. Clin Exp Dermatol 1998; 23: 95.
29. Cameli N, Vicenzi C, Tosti A. Allergic contact conjunctivitis due to timolol in eyedrops. Contact Dermatitis 1991; 25: 129-30.
30. Katz IM. Beta-blockers and the eye: an overview., Ann Ophthalmol 1978; 10: 847-50.
31. Aoki J. Allergic contact dermatitis due to eye drops. Their clinical features and the patch test results. Nippon Ika Daigaku Zasshi 1997; 64: 232-7.
32. Giordano-Labadie F, Lepoittevin JP, Calix I, Bazex J. Contact allergy to beta blockaders in eye drops: cross allergy? Ann Dermatol Venereol 1997; 124: 322-4.
33. Nino M, Suppa F, Ayala F, Balato N. Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol. Contact Dermatitis 2001 , 44: 369.
34. Corazza M, Virgili A, Mantovani L, Masieri LT. Allergic contact dermatitis from cross-reacting beta-blocking agents. Contact Dermatitis 1993; 28: 188-9.
35. O'Donnell BF, Foulds IS. Contact allergy to beta-blocking agents in opthalmic preparations. Contact Dermatitis 1993; 28: 121-2.
36. Quiralte J, Florido F, de San Pedro BS. Allergic contact dermatitis from carteolol and timolol in eyedrops. Contact Dermatitis 2000; 42: 245.
37. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115: 45-9.
38. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995; 113: 1009-16.
39. Aalto-Korte K. Contact allergy to dorzolamide eyedrops. Contact Dermatitis 1998, 39: 206.
40. Shimada M, Higaki Y, Kawashima M. Allergic contact dermatitis due to dorzolamide eyedrops. Contact Dermatitis 2001; 45: 52.
41. Mancuso G, Berdondini RM. Allergic contact blepharoconjunctivitis from dorzolamide. Contact Dermatitis 2001; 45: 243.
42. Linares Mata T, Pardo Sanchez J, de la Cuadra Oyanguren J. Contact dermatitis caused by allergy to dorzolamide. Contact Dermatitis 2005; 52: 111-2.
43. Jerstad KM, Warshaw E. Allergic contact dermatitis to latanoprost. Am J Contact Dermat 2002; 13: 39-41.
44. Herbst RA, Maibach HI. Contact dermatitis caused by allergy to ophthalmic drugs and contact lens solutions. Contact Dermatitis 1991; 25: 305-12.
45. Schorr WF, Ridgway HB. Tobramycin-neomycin cross-sensitivity. Contact Dermatitis 1977; 3: 133-7.
46. Rudzki E, Zakrzewski Z, Rebandel P, Grzywa Z, Hudymowicz, W. Cross reactions between aminoglycoside antibiotics. Contact Dermatitis 1988, 18: 314-6.
47. Pelta R. Reacciones adversas por medicamentos de uso tópico. In: Pelta R, Vivas E, editors. Reacciones adversas a medicamentos. Valoración clinica. Madrid: Ediciones Díaz de Santos S.A. 1992; 221-39.
48. Mathelier-Fusade P, Leynadier F. Cross-reactions in contact dermatitis. Clin Rev Allergy Immunol 1997; 15: 477-84.
49. Menéndez Ramos F, Llamas Martín R, Zarco Olivo C, Dorado Bris JM, Merino Luque MV. Allergic contact dermatitis from tobramycin. Contact Dermatitis 1990; 22: 305-6.
50. Caraffini S, Assalve D, Stingeni L, Lisi P. Allergic contact conjunctivitis and blepharitis from tobramycin. Contact Dermatitis 1995; 32: 186-7.
51. González-Mendiola MR, Balda AG, Delgado MC, Montaño PP, De Olano DG, Sánchez-Cano M. Contact allergy from tobramycin eyedrops. Allergy 2005; 60: 527-8.
52. Cronin E. Contact dermatitis. Edinburgh: Churchill Livingstone, 1980; 209
53. Cooper SM, Shaw S. Eyelid dermatitis: an evaluation of 232 patch test patients over 5 years. Contact Dermatitis 2000: 42: 291-3.
54. Frosch PJ, Weickel R, Schmitt T, Krastel H. Nebenwirkungen von ophthalmologischen externa. Z Hautkr 1988: 63: 126-36.
55. Sánchez-Pérez J, López MP, de Vega Haro MJM, García-Díez A. Contact dermatitis from gentamicin in eyedrops, with cross-reactivity to kanamycin but not neomycin. Contact Dermatitis 2001; 44: 47.
56. Rietschel RL, Fowler JF. Reactions to topical antimicrobials. In: Fisher's contact dermatitis, 4th edition. Baltimore: Williams and Wilkins, 1995; 213.
57. Muñoz-Bellido FJ, Moyano JC, Alvarez M, Juan JL, Bellido J. Contact sensitivity to gentamicin with tolerance of systemic exposure. Allergy 1996; 51: 758-9.
58. Katayama I, Nishioka K. Systemic contact dermatitis medicamentosa induced by topical eye lotion (sisomicin) in a patient with corneal allograft. Arch Dermatol 1987; 123: 436-7.
59. Melchior EJ, Samsoen M, Foussereau J, Grosshans E. Quels sont les médicaments topiques les plus sensibilisants de la pharmacopée française?. Rev Praticien 1979; 29: 3535-7.
60. Riboldi A, Pigatto PD, Morelli M, Altomare GF, Polenghi MM. Allergy to mercurochrome and rifamycin. Contact Dermatitis 1985; 12: 180.
61. Milpied B, van Wassenhove L, Larousse C, Barriere H. Contact dermatitis from rifamycin. Contact Dermatitis 1986; 14: 252-3.
62. Balato N, Lembo G, Patruno G, Ayala F. Allergic contact dermatitis from rifamycin. Contact Dermatitis 1988; 19: 310.
63. Guerra L, Adamo F, Venturo N, Tardio M. Contact dermatitis due to rifamycin. Contact Dermatitis 1991; 25: 328.
64. García F, Blanco J, Carretero P, Herrero D, Juste S, Garcés M, et al. Anaphylactic reactions to topical rifamycin. Allergy 1999; 54: 527.
65. Genvert GI, Cohen EJ, Donnenfeld ED, Blecher MH. Erythema multiforme, after use of topical sulfacetamide. Am J Ophthalmol 1985; 99: 465-8.
66. Hwu JJ, Chen KH, Hsu WM, Lai JY, Li YS. Ocular hypersensitivitiy to topical vancomycin in a case of chronic endophthalmitis. Cornea 2005; 24: 754-6.
67. Holdiness MR. Contact dermatitis from topical antiviral drugs. Contact Dermatitis 2001; 44: 265-9.
68. Valsecchi R, Imberti G, Cainelli T. Contact allergy to acyclovir. Contact Dermatitis 1990; 23: 372-3.
69. Pigatto PD, Bigardi A, Legori A, Altomare GF, Riboldi A. Allergic contact dermatitis from beta-interferon in eyedrops. Contact Dermatitis 1991; 25: 199-200.
70. Amon RB, Lis AW, Hanifin JM. Allergic contact dermatitis caused by idoxuridine. Arch Dermatol 1975; 111: 1581-4.
71. Calnan CD. Contact dermatitis of idoxuridine. Contact Dermatitis 1976; 2: 58.
72. van Ketel W G. Allergy to idoxuridine eye drops. Contact Dermatitis 1977; 3: 106-7.
73. Thormarm J, Wildenhoff KE. Contact allergy to idoxuridine. Sensitization following treatment of herpes zoster. Contact Dermatitis 1980; 6: 170-1.
74. Lombardi P, Spallanzani P, Giorgini S, Seroli A. Allergic contact dermatitis from idoxuridine. Contact Dermatitis 1982; 8: 350-1.
75. Naito T, Shiota H, Mimura Y. Side effects in the treatment of herpetic keratitis. Curr Eye Res 1987; 6: 237-9.
76. Senff H, Engelmann L, Kunze J, Hansen BM. Allergic contact dermatitis from idoxuridine. Contact Dermatitis 1990; 23: 43-5.
77. Millan-Parrilla F, de La Cuadra J. Allergic contact dermatitis from trifluoridine in eye drops. Contact Dermatitis 1990; 22: 289.
78. Cirkel P, van Ketel W. Allergic contact dermatitis to trifluorthymidine eye drops. Contact Dermatitis 1981; 7: 49-50.
79. Sheehan GJ, Kutzner MR, Chin WD. Acute asthma attack due to ophthalmic indomethacin. Ann Intern Med 1989; 111: 337-8.
80. Sharir M. Exacerbation of asthma by topical diclofenac. Arch Ophthalmol 1997; 115: 294-5.
81. Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA. Asthma caused by topical application of ketorolac. Ophthalmology 1996; 103: 890-2.
82. Ueda K, Higashi N, Kume A, Ikushima-Fujimoto M, Ogiwara S. Allergic contact dermatitis due to diclofenac and indomethacin. Contact Dermatitis 1998; 39: 323.
83. Dannaker CJ, Maibach HI, Austin E. Allergic contact dermatitis to proparacaine with subsequent cross-sensitization to tetracaine from ophthalmic preparations. Am J Contact Dermat 2001; 12: 177-9.
84. Parente G, Pazzaglia, M, Vincenzi C, Tosti A. Contact dermatitis from pheniramine maleate in eyedrops. Contact Dermatitis 1999; 40: 338.
85. Camarasa JG, Serra-Baldrich E, Monreal P, Soller J. Contact dermatitis from sodium-cromoglycate-containing eyedrops. Contact Dermatitis 1997; 36: 160-1.
86. McLelland J, Shuster S. Contact dermatitis with negative patch tests: the additive effect of allergens in combination. Br J Dermatol 1990; 122: 623-30.
87. Kellett JK, King CM, Beck MH. Compound allergy to medicaments. Contact Dermatitis 1986; 14: 45-8.
88. Blanco R, Quirce S, Pedraza L, Diez-Gomez ML. Allergic conjunctivitis from eyedrops. Allergy 1997; 52: 686-7.
89. Yamashita H, Kawashima M. Contact dermatitis from amlexanox eyedrops. Contact Dermatitis 1991; 25: 255-6.
90. Miyamoto H, Okajima M. Allergic contact dermatitis from epsilon-aminocaproic acid. Contact Dermatitis 2000; 42: 50.
91. De Moor A, Van Hecke E, Kestelyn P. Contact allergy to penicillamine in eyedrops. Contact Dermatitis 1993; 29: 155-6.
92. Assem ES, Vickers MR. Immunological response to penicillamine in penicillin-allergic patients and in normal subjects. Postgrad Med J 1974; 50(Suppl 2): 65-71.
93. Davison SC, Wakelin SH. Allergic contact dermatitis from N-acetylcysteine eyedrops. Contact Dermatitis 2002; 47: 238.
94. Wictorin A, Hansson C. Allergic contact dermatitis from a bismuth compound in an eye ointment. Contact Dermatitis 2001; 45: 318.
95. Bernstein DI, Gallagher JS, Grad M, Bernstein IL. Local ocular anaphylaxis to papain enzyme contained in a contact lens cleansing solution. J Allergy Clin Immunol 1984; 74: 258-60.
96. Cameli N, Bardazzi F, Morelli R, Tosti A. Contact dermatitis from rubidium iodide in eyedrops. Contact Dermatitis 1990; 23: 377-8.
97. Kirby B, Butt A, Morrison AM, Beck MH. Type I allergic reaction to hyaluronidase during ophthalmic surgery. Contact Dermatitis 2001; 44: 52.
98. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002, 53: 263-80.
99. Tosti A, Tosti G. Thimerosal: a hidden allergen in ophthalmology. Contact Dermatitis 1988; 18: 268-73.
100. Iliev D, Wuthrich B. Conjunctivitis to thimerosal mistaken as hay fever. Allergy 1998; 53: 333-4.
101. Corazza M, Virgili A. Allergic contact dermatitis from ophthalmic products: can pre-treatment with sodium lauryl sulfate increase patch test sensitivity? Contact Dermatitis 2005; 52: 239-41.
102. Mousa SA, Mousa AS. Angiogenesis inhibitors: current & future directions. Curr Pharm Des 2004; 10(1): 1-9.
103. Stitt AW, Frizzell N, Thorpe SR. Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr Pharm Des 2004; 10(27): 3349-60.
104. Wegewitz U, Gobring I, Spranger J. Novel approaches in the treatment of angiogenic eye disease. Curr Pharm Des 2005; 11 (18): 2311-30.